Written and maintained by CASRAI Editorial Board
Published · Last updated
On this page
Short answer: BARDA is the Biomedical Advanced Research and Development Authority, a unit established by federal statute within the U.S. Department of Health and Human Services. Its job is to develop medical countermeasures for chemical, biological, radiological and nuclear incidents, pandemic influenza and emerging infectious diseases, and it works on products after basic research and preclinical development.
General information only, not medical advice. This page is written for researchers, laboratory and clinic staff and anyone tracing how countermeasure development connects to supply decisions.
Definition and scope
BARDA’s own website describes it as part of the Administration for Strategic Preparedness and Response (ASPR) within HHS, with a mission to “develop medical countermeasures that address the public health and medical consequences” of chemical, biological, radiological and nuclear (CBRN) incidents, pandemic influenza and emerging infectious diseases. The legal basis is 42 U.S.C. 247d-7e (section 319L of the Public Health Service Act), which states that the Authority is established within HHS and is headed by a Director appointed by the Secretary.
The statute defines “advanced research and development” as activities conducted predominantly after basic research and preclinical development of a product. That definition places BARDA downstream of the laboratory discovery stage. For a different federal health research agency, see the CASRAI entry on ARPA-H.
How BARDA works in practice
According to BARDA’s site (checked 2026-10-31), the organization is divided into operating units, including:
- CBRN
- Clinical Development
- Contract Management and Acquisition
- Detection, Diagnostics, and Devices Infrastructure
- Nonclinical Development
- Research, Innovation and Ventures (DRIVe)
- Influenza and Emerging Infectious Diseases
- Pharmaceutical Countermeasures and Infrastructure
- Regulatory and Quality Affairs
The site lists the routes through which developers engage: a Broad Agency Announcement (BAA) with stated Areas of Interest, an Easy BAA (EZ-BAA), and TechWatch meetings for presenting ideas. DRIVe is described as providing “proof-of-concept and research and development funding, as well as acceleration resources.” The site also names initiatives such as Project NextGen, REMM, PRISM and CHEMM.
BARDA’s site states figures that may change over time: 116 FDA approvals, licensures and clearances for BARDA-supported products, and a Contract Management and Acquisition unit overseeing about $1.7 billion in annual spending and a contract portfolio above $60 billion (as stated on the site, checked 2026-10-31).
What the law says: statute and practice side by side
The comparison below pairs each provision of 42 U.S.C. 247d-7e that this page relies on with the plain meaning of its text. Every row comes from the statute as published by the Cornell Legal Information Institute (checked 2026-10-31).
| Provision | What the text says | What it means in practice |
|---|---|---|
| Subsection (c)(1) | “There is established within the Department of Health and Human Services” the Authority. | BARDA exists by statute, not only by agency organization chart. |
| Subsection (c)(3) | Headed by a Director “appointed by the Secretary.” | The Director is appointed by the HHS Secretary. |
| Subsection (a)(6)(A) | Advanced research and development is activity predominantly “conducted after basic research and preclinical development of the product.” | The remit starts after discovery-stage science. |
| Subsection (c)(2) | The Secretary “shall coordinate the acceleration of countermeasure and product advanced research and development.” | The mandate is acceleration and coordination of development. |
| Subsection (c)(4)(B)(iii) | The activities the statute lists include to “establish strategic initiatives to accelerate countermeasure and product advanced research and development.” | Strategic initiatives to speed development are among the listed activities. |
| Subsection (a)(3) and (c)(5)(A) | “Other transactions” means transactions other than procurement contracts, grants and cooperative agreements; the Secretary has authority to enter into them, and “to the maximum extent practicable, competitive procedures shall be used.” | Agreements outside the usual contract and grant forms are allowed, with a competition expectation. See the CASRAI guide to other transaction authority versus grants and contracts. |
Where it matters for labs, clinics and supply decisions
Countermeasures are only useful if they can be held and distributed. The Strategic National Stockpile statute, 42 U.S.C. 247d-6b, directs the Secretary, with the Assistant Secretary for Preparedness and Response and the CDC Director and in coordination with the Secretary of Homeland Security, to “maintain a stockpile or stockpiles of drugs, vaccines and other biological products, medical devices, and other supplies.” Security countermeasures may be procured “with amounts in the special reserve fund,” and those identified for procurement are ones “appropriate for inclusion in the stockpile.” The CASRAI guide to the Strategic National Stockpile covers that program, and the guide to the Shelf Life Extension Program covers what happens to stockpiled product as it ages. For local planning, see disaster relief medical supply cache planning.
For laboratory and clinic staff, the practical reading is that development support (BARDA) and stockpile maintenance (a separate statutory provision) are linked parts of one preparedness chain, not one program. This page gives no purchasing, pricing or stock guidance.
Common misunderstandings
BARDA is not a basic-research grant program
The statutory definition of advanced research and development begins after basic research and preclinical development. Basic science funding sits elsewhere.
BARDA is not the Strategic National Stockpile
The stockpile provision in 42 U.S.C. 247d-6b is addressed to the Secretary, ASPR and the CDC Director. The BARDA provision is a separate section of the Public Health Service Act.
BARDA is not the same agency as ARPA-H
They are separate entities with separate mandates; the ARPA-H entry explains the other side.
FAQ
What does BARDA stand for?
Biomedical Advanced Research and Development Authority, established within HHS by 42 U.S.C. 247d-7e(c)(1).
Who runs BARDA?
A Director appointed by the HHS Secretary, under subsection (c)(3). The Authority sits within ASPR according to BARDA’s own site.
How can a developer engage with BARDA?
BARDA’s site lists a Broad Agency Announcement with Areas of Interest, an Easy BAA (EZ-BAA) and TechWatch meetings. Check the site’s current announcements for eligibility and terms.
Does BARDA use grants?
The statute separately authorizes “other transactions,” defined as transactions other than procurement contracts, grants and cooperative agreements, so the agency’s tools are not limited to a single form.
Sources
- BARDA, medicalcountermeasures.gov/barda (HHS/ASPR), checked 2026-10-31.
- 42 U.S.C. 247d-7e, Biomedical Advanced Research and Development Authority, Cornell Legal Information Institute, checked 2026-10-31.
- 42 U.S.C. 247d-6b, Strategic National Stockpile, Cornell Legal Information Institute, checked 2026-10-31.







